EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.25
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$31.98

11 Apr
2024

0.050

OPEN

$31.77

0.16%

HIGH

$31.98

10,269

LOW

$31.49

TARGET
$35.68 11.6% upside
Franking for last dividend paid out: 96%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 150.5 xxx
DPS (cps) xxx N/A 102.2 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 21.3 xxx
Dividend Yield xxx N/A 3.2% xxx
Div Pay Ratio(%) xxx N/A 67.9% xxx

Dividend yield today if purchased 3 years ago: 1.92%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

1.63

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 47.56c (franking 96%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx132.9
DPS All xxxxxxxxxxxxxxx107.9
Sales/Revenue xxxxxxxxxxxxxxx12,237.4 M
Book Value Per Share xxxxxxxxxxxxxxx1,270.5
Net Operating Cash Flow xxxxxxxxxxxxxxx391.4 M
Net Profit Margin xxxxxxxxxxxxxxx2.07 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx10.78 %
Return on Invested Capital xxxxxxxxxxxxxxx7.07 %
Return on Assets xxxxxxxxxxxxxxx3.99 %
Return on Equity xxxxxxxxxxxxxxx10.78 %
Return on Total Capital xxxxxxxxxxxxxxx12.06 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx121.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx92 M
Long Term Debt xxxxxxxxxxxxxxx1,191 M
Total Debt xxxxxxxxxxxxxxx1,283 M
Goodwill - Gross xxxxxxxxxxxxxxx1,976 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx212 M
Price To Book Value xxxxxxxxxxxxxxx2.66

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx98.4 M
Capex % of Sales xxxxxxxxxxxxxxx0.80 %
Cost of Goods Sold xxxxxxxxxxxxxxx11,322 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx470 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx69 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

22/02/2024

5

Sell

$33.00

3.19%

On Citi's assessment, Ebos Group delivered an in-line H1 performance and growth indications for H2 are consistent with H1. The broker estimates losing the Chemist Warehouse contract creates a -$80m headwind for FY25.

Management is targeting cost efficiences to the tune of $25m-50m, with more details to be provided with the publication of FY24 financials.

Estimates have been lifted by 2%-4% for the years ahead. As Citi maintains the loss of the sizable contract is not yet reflected in the share price, the rating remains Sell.

Target price increases by $1 to $33.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

4

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

EBO STOCK CHART